Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Samsung Bioepis

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

Biogen Idec building

Biogen cuts $217m deal for Karyopharm neurology drug

The biotech hopes to begin phase I trials of KPT-350 by the end of the year

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

Biogen Idec building

NICE finally starts review of Biogen’s Spinraza for SMA

Will evaluate the treatment based on its Single Technology Appraisal process

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

- PMLiVE

Biogen appoints Jeff Capello as executive VP and CFO

He will lead the company's business and finance planning functions

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

Biogen Idec building

Biogen says trial extension data keep Alzheimer’s drug on track

Releases updated results from the PRIME trial of anti-amyloid drug aducanumab

- PMLiVE

New EU and US approvals for Humira biosimilars

Samsung’s Imraldi and Boehringer Ingelheim’s Cyltezo receives nod from EMA and FDA, respectively

- PMLiVE

Samsung deal with Takeda looks beyond biosimilars

The duo plan to develop “multiple novel biologic therapies”

- PMLiVE

Biogen expands digital safety platform Assessa

The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links